MedTrace Logo

Oncologic Therapy Support Via Means of a Dedicated Mobile App

NCT03168048 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2017-05-30

No results posted yet for this study

Summary

The present single-center prospective exploratory study, conducted at Heidelberg University Hospital, assesses the feasibility of introducing a concept for additional patient care based on a mobile application for patients undergoing radiotherapy. Patients presenting themselves for the irradiation of thoracic or pelvic tumors will be surveyed regarding general performance, treatment-related Quality of Life (QoL) and symptoms and their need to personally consult a physician on a treatment-daily basis by means of a mobile application. The primary endpoint of feasibility will be reached when 80% of the patients have successfully answered 80% of their respective questions scheduled for each treatment day. Furthermore, treatment-related patient satisfaction and diagnosis-related QoL is assessed by PSQ-18 and EORTC questionnaires at the end of radiotherapy and at the first follow-up.

Conditions

  • Thoracic Neoplasm
  • Pelvic Neoplasm
  • Radiotherapy; Complications
  • Oncologic Disorders
  • Breast Cancer
  • Satisfaction
  • Quality of Life

Interventions

OTHER

mobile application

Oncologic therapy support by means of a mobile application

Sponsors & Collaborators

  • Heidelberg University

    lead OTHER

Principal Investigators

  • Nils Nicolay, PD Dr. Dr. · Heidelberg Institute of Radiation Oncology (HIRO)

Study Design

Allocation
NA
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-31
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03168048 on ClinicalTrials.gov